TOELY has performed on-par with the rest of the sector throughout the Covid era, despite its OTC status and comparative obscurity for ordinary traders (70B mkt cap vs ASML, AMAT etc). Another new ATH reached just before earnings, and a rosy outlook ahead. Rising support levels still accelerating, price action above all meaningful MAs. On track for more gains towards the 135-145 target.
註釋
Retested the "new support" on 04-05 May, and it has unsurprisingly held.免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。